Sankala Group’s Royalty Pharma RPRX Stock Holding History

Sankala Group’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.8K	Hold	197	–	–	0.01%	375
2026 Q1	$9.3K	Hold	197	–	–	0.01%	391
2025 Q4	$9.1K	Buy	+197	New	+$7.51K	0.01%	399

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sankala Group's RPRX Position: Q2 2026 in Review

Sankala Group held its Royalty Pharma (RPRX) position steady in Q2 2026 at 197 shares worth $11.8K. The position accounts for 0.01% of the portfolio, ranked #375.

Sankala Group first reported a position in RPRX in Q4 2025 and has held it in 3 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Sankala Group held 197 shares of Royalty Pharma worth $11.8K as of Q2 2026.
Sankala Group left its Royalty Pharma share count unchanged in Q2 2026.
Royalty Pharma made up 0.01% of Sankala Group's portfolio in Q2 2026, its #375 holding.
Sankala Group first reported a position in Royalty Pharma in Q4 2025 and has held it in 3 quarters since.
647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Sankala Group's 13F filing for Q2 2026, filed 18 Aug 2026.